Pregled bibliografske jedinice broj: 1274029
IMPACT OF IMMUNOHISTOCHEMICAL CHARACTERISTICS OF TUMOR ON RESPONSE TO DUAL ANTI-HER2 BLOCKADE – DATA FROM REAL CLINICAL PRACTICE
IMPACT OF IMMUNOHISTOCHEMICAL CHARACTERISTICS OF TUMOR ON RESPONSE TO DUAL ANTI-HER2 BLOCKADE – DATA FROM REAL CLINICAL PRACTICE // Libri Oncologici
Zagreb, 2023. str. 68-69 (poster, domaća recenzija, sažetak, stručni)
CROSBI ID: 1274029 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
IMPACT OF IMMUNOHISTOCHEMICAL CHARACTERISTICS
OF TUMOR ON RESPONSE TO DUAL ANTI-HER2 BLOCKADE
– DATA FROM REAL CLINICAL PRACTICE
Autori
Linarić, Petra ; Pavlović Mavić, Mirjana ; Mirčevski, Karla ; Meštrović, Josipa ; Jakšić, Petra ; Tečić Vuger, Ana ; Vazdar, Ljubica ; Šeparović, Robert
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Libri Oncologici
/ - Zagreb, 2023, 68-69
Skup
16th Croatian oncology congress
Mjesto i datum
Poreč, Hrvatska, 20.04.2023. - 23.04.2023
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
HER2 positive breast cancer, dual anti-HER2 blockade, immunohistochemistry
Sažetak
Results of our research showed that there was no statistically significant difference in duration of treatment between patients with luminal and non-luminal subtype, same as was reported in CLEOPATRA trial. Analyzing correlation between duration of treatment and HER2 receptor expression, there was no statistically significant difference between subgroups with 3+ and 2+ expression. This was not concordant with referent trial results, which have shown shorter progression free survival in subgroup with lower HER2 receptor expression (2+), without impact on overall survival.
Izvorni jezik
Engleski
POVEZANOST RADA
Profili:
Mirjana Pavlović
(autor)
Ana Tečić Vuger
(autor)
Ljubica Vazdar
(autor)
Robert Šeparović
(autor)